In clinical samples, tumour microarray experiments confirmed a positive correlation between the expression levels of Raf1 and Pkm2 in tumour tissue, suggesting that Raf1‐Pkm2 may serve as a synergistic therapeutic target for HCC development. Here, PKM is linked to hepatocellular carcinoma.